Anbio BiotechnologyNNNN
13F holders, Q2 2025 (June 30)5holders +2
3new positions
1sold out
$31.66avg. 13F price*
At the end of Q2 2025, 5 institutions reported holding Anbio Biotechnology Ltd. (NNNN) in their 13F filings, up 2 from Q1 2025. 3 opened new positions and 1 sold out. The largest holders were Geode Capital Management, LLC ($542K), UBS Group AG ($339K) and BNP Paribas Financial Markets ($40K).
- Company
- Anbio Biotechnology Ltd.
- CUSIP
- G0367B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $56K |
| Exits | 1 | $325K |
All 13F filers, Q1 2025 → Q2 2025: 6,788 shares bought and 43,629 shares sold, net −36,841 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Geode Capital Management, LLC | 0.00% | Add +0.4% | 17,130 | $542K |
| UBS Group AG | 0.00% | Add +86.4% | 10,695 | $339K |
| BNP Paribas Financial Markets | 0.00% | New | 1,261 | $40K |
| Morgan Stanley | 0.00% | New | 400 | $13K |
| Wells Fargo & Company | 0.00% | New | 100 | $3K |
"% of holder's portfolio" is NNNN's weight in each manager's 13F, not the share of Anbio Biotechnology Ltd. the manager owns.